ConductScience.org, home

Trial · NCT00098371

Results by group24

Each measurement the trial posted, group by group, in the words and numbers it posted.

OutcomeGroupCategoryValueSpreadUnits
Complete Response (CR) RateTreatment (Alvocidib)2percent of patients
Overall Response Rate (CR + PR)Treatment (Alvocidib)5395% Confidence Interval 41 to 65percent of patients
Progression-free Survival (PFS) for Responding Patients as Assessed Using Standard Kaplan-Meier MethodsTreatment (Alvocidib)1295% Confidence Interval 8.5 to 13.1months
Progression-free Survival for All Patients as Assessed Using Standard Kaplan-Meier MethodsTreatment (Alvocidib)8.695% Confidence Interval 6.7 to 12.6months
Overall SurvivalTreatment (Alvocidib)28.895% Confidence Interval 18.6 to 32.9months
ToxicityTreatment (Alvocidib)25percentage of patients
Pharmacokinetics (PK) (AUC) as Assessed by Plasma Levels of Both Flavopiridol and Metabolites of FlavopiridolTreatment (Alvocidib)9.42Standard Deviation 5.11μM*hr
PK (Cmax) as Assessed by Plasma Levels of Both Flavopiridol and Metabolites of FlavopiridolTreatment (Alvocidib)2.04Standard Deviation 1.05μM
Serial Levels of IL-6 as Assessed by Blood PlasmaGroup 14.5 hours3.595% Confidence Interval 2.7 to 4.6pg/ml
Serial Levels of IL-6 as Assessed by Blood PlasmaGroup 24.5 hours1.695% Confidence Interval 1.2 to 2.0pg/ml
Serial Levels of IL-6 as Assessed by Blood PlasmaGroup 18 hours13.495% Confidence Interval 9.8 to 18.4pg/ml
Serial Levels of IL-6 as Assessed by Blood PlasmaGroup 28 hours2.295% Confidence Interval 1.7 to 2.9pg/ml
Serial Levels of IL-6 as Assessed by Blood PlasmaGroup 112 hours25.595% Confidence Interval 17.3 to 37.6pg/ml
Serial Levels of IL-6 as Assessed by Blood PlasmaGroup 212 hours2.595% Confidence Interval 1.8 to 3.6pg/ml
Serial Levels of IL-6 as Assessed by Blood PlasmaGroup 124 hours13.295% Confidence Interval 8.0 to 21.7pg/ml
Serial Levels of IL-6 as Assessed by Blood PlasmaGroup 224 hours3.995% Confidence Interval 2.5 to 6.2pg/ml
Correlation of Adverse Prognostic Factors With Response to Flavopiridol Treatment as Assessed by Interphase Cytogenetics, VH Mutational Status, ZAP-70 Protein Expression, CD38, and p53Patients With Del(17p13.1)57percentage of patients in each subgroup
Correlation of Adverse Prognostic Factors With Response to Flavopiridol Treatment as Assessed by Interphase Cytogenetics, VH Mutational Status, ZAP-70 Protein Expression, CD38, and p53Patients Without Del(17p13.1)51percentage of patients in each subgroup
Correlation of Adverse Prognostic Factors With Response to Flavopiridol Treatment as Assessed by Interphase Cytogenetics, VH Mutational Status, ZAP-70 Protein Expression, CD38, and p53Patients With Del(11q22.3)50percentage of patients in each subgroup
Correlation of Adverse Prognostic Factors With Response to Flavopiridol Treatment as Assessed by Interphase Cytogenetics, VH Mutational Status, ZAP-70 Protein Expression, CD38, and p53Patients Without Del(11q22.3)56percentage of patients in each subgroup

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT00098371/results